Nabriva Therapeutics Sets Terms For IPO

Source: ThinkstockNabriva Therapeutics AG filed an amended F-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO) in the U.S. The filing set terms for the IPO with each American Depositary share (ADS) having an expected price range of $15 to $17 for 6 million ADSs; each ADS represents […]

Source: Nabriva Therapeutics Sets Terms For IPO

#ReadingNow …. this is what I read that I really think we all need to just generally know about going forward:  “This is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics.”  (Emphasis added)

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s